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Abstract 
AIMS A population pharmacokinetic (PK) analysis was performed to: (1) characterise the PK of 
unbound and total mycophenolic acid (MPA) and its 7-O-mycophenolic acid glucuronide (MPAG) 
metabolite, and (2) identify the clinically significant covariates that cause variability in the 
dose-exposure relationship to facilitate dose optimisation. 
METHODS A total of 740 unbound MPA (uMPA), 741 total MPA (tMPA) and 734 total MPAG 
(tMPAG) concentration-time data from 58 Chinese kidney transplant patients were analysed using a 
nonlinear mixed-effect model. The influence of covariates was tested using a stepwise procedure. 
RESULTS The PK of unbound MPA and MPAG were characterised by a two- and one-compartment 
model with first-order elimination, respectively. Apparent clearance of uMPA (CLuMPA/F) was 
estimated to be 852 L/h with a relative standard error (RSE) of 7.1%. The tMPA and uMPA were 
connected using a linear protein binding model, in which the protein binding rate constant (kB) 
increased non-linearly with the serum albumin (ALB) concentration. The estimated kB was 53.4 /h 
(RSE, 2.3%) for patients with ALB of 40 g/L. In addition, model-based simulation showed that 
changes in ALB substantially affected tMPA but not uMPA exposure. 
CONCLUSIONS The established model adequately described the population PK characteristics of the 
uMPA, tMPA, and MPAG. The estimated CLuMPA/F and unbound fraction of MPA (FUMPA) in Chinese 
kidney transplant recipients were comparable to those published previously in Caucasians. We 
recommend monitoring uMPA instead of tMPA to optimise mycophenolate mofetil (MMF) dosing for 
patients with lower ALB levels. 
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Introduction 
Mycophenolate mofetil (MMF), a pro-drug of mycophenolic acid (MPA), is the predominant 
antimetabolite immunosuppressant used as a co-therapy with tacrolimus (TAC) or ciclosporin (CsA) to 
prevent graft rejection after solid organ transplantation [1, 2]. MMF is extensively absorbed and rapidly 
hydrolysed to the active component MPA after oral administration. The latter is primarily metabolised 
to the major but inactive 7-O-mycophenolic acid glucuronide (MPAG) and the relatively minor but 
active acyl-glucuronide mycophenolic acid (AcMPAG) [3, 4]. MPA and MPAG are reported to be 97% 
and 82% bound to serum albumin (ALB) at clinically relevant concentrations, respectively [3]. MPAG 
also undergoes the enterohepatic circulation (EHC) through biliary excretion, intestinal 
de-glucuronidation by microflora, and reabsorption as MPA in the colon. This process contributes to 
approximately 40% (range: 10–60%) of the area under the concentration-time curve (AUC) of MPA 
and causes multiple peaks in the concentration-time profile [3, 5]. Most absorbed MMF is eliminated 
through the kidney as MPAG [5]. 
MPA has a narrow therapeutic window. It is recommended to maintain a 12-h dosing interval 
exposure (AUC0-12h) between 30 and 60 mg·h/L during the early post-transplantation period when 
MMF is prescribed with CSA [6-9]. Under-exposure is associated with an increased risk for acute 
rejection, whereas a higher AUC0-12h may lead to over-immunosuppression. Large between-subject 
variability (BSV) and time-dependent variation within-subject are characteristics of MPA 
pharmacokinetics (PK) [10-12]. A 10-fold variation of MPA exposure was observed even in subjects 
administered the same dose during the first 2 weeks following kidney transplantation. Moreover, the 
AUC of MPA in the first few weeks post-transplantation was 30–50% lower than that in the later period 
following administration of the same dose of MMF [10]. 
The narrow therapeutic window and large PK variability make it necessary to individualise MMF 
therapy based on therapeutic drug monitoring (TDM). Currently, the maximum a posterior Bayesian 
(MAPB) method using population PK in combination with Bayesian estimation is recommended for 
facilitating the optimal pharmacotherapy [13-16]. This approach is based on a comprehensive 
understanding of prior information, i.e. the population PK characteristics. 
The population PK characteristics of total MPA (tMPA) in kidney transplant recipients have been 
extensively investigated in various populations and no obvious ethnic difference has been observed in 
tMPA population PK [17-26]. There are few investigations of the population PK characteristics of 
unbound MPA (uMPA) [27-30], the pharmacologically active component, due to the technical 
complexity of measurements. Furthermore, little is known in Chinese kidney transplant recipients. 
Therefore, the aims of this study were to develop a population PK model to: (1) characterise the PK of 
uMPA, tMPA, and the metabolite MPAG, and (2) identify the clinically significant covariates that cause 
variability in the dose-exposure relationship to facilitate dose optimisation. 
Methods 
Study design and patients 
The data were obtained from two clinical studies conducted in 58 Chinese adult kidney transplant 
recipients [31, 32]. All recipients received triple immunosuppressive therapy comprising MMF 
(CellCept®, Roche Pharma Ltd., Shanghai, China), CsA, and corticosteroids. The first study was an 
evaluation of the PK of MPA and MPAG during the early post-transplantation period conducted at 
Huashan Hospital, Fudan University [31]. MMF was initiated at 1500 mg/day from the day of the 
surgery. The second study was an open-label, multi-centre, two-phase, sequential, bioequivalence study 
conducted in stable kidney transplantation patients [32]. MMF dose was 1000 or 1500 mg/day in most 
patients. All protocols were approved by the independent Clinical Research Ethics Committee of 
Huashan Hospital, Fudan University and all participants provided written informed consent before 
enrolment. 
After the morning dose, whole blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 
12 h in study 1, and at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 10, and 12 h in study 2. Low-fat meals were 
provided after the scheduled 4 and 10 h samplings in study 1, and the 3 and 9 h samplings in study 2. 
The relevant data were collected to explore the relationships between demographic characteristics, 
biochemical measurements, and PK parameters. 
All samples were analysed at Huashan Hospital using a validated high-performance liquid 
chromatography method [31, 33]. The calibration ranges were 0.002–1.0, 0.1–40, and 10–200 mg/L for 
uMPA, tMPA, and total MPAG (tMPAG), respectively. The relative bias values were within ±17%, 
±8.3%, and ±5.2% for uMPA, tMPA, and tMPAG, respectively. The intra- and inter-day precision, as 
coefficient of variation values, were < 10% and 14% for uMPA, 5.1% and 9.2% for tMPA, and 6.7% 
and 9.8% for tMPAG, respectively. 
Population PK analyses 
Software and model selection criteria 
Population PK analyses were performed using the nonlinear mixed-effect modelling software 
(NONMEM
®
, version 7.4; ICON Development Solutions, Ellicott City, MD, USA) compiled with 
gfortran 4.6.0. Perl-speaks-NONMEM (PsN, version 4.7.0; http://uupharmacometrics.github.io/PsN) 
and Pirana (version 2.9.7; http://www.certara.com/pirana) were used to link NONMEM, model 
development, and model evaluation. The stochastic approximation expectation maximisation (SAEM), 
followed by important sampling (IMP) method [34] were used throughout the model development. 
Graphical diagnostics were performed using R software (version 3.4.4, http://www.r-project.org). 
MMF doses and uMPA, tMPA, and tMPAG concentrations were transformed into molar 
equivalents by dividing them with the molecular weight (MMF, MPA, and MPAG: 433.498, 320.339, 
and 496.462 g/mol, respectively; http://chem.nlm.nih.gov/chemidplus/) and then reconverted to 
milligram per litre in the figures and results. 
Model selection was based on goodness-of-fit (GOF) plots [35] in addition to the three commonly 
used criteria of statistical significance, plausibility, and stability. The difference in objective function 
values (OFV) between two nested models was used for statistical comparison. Akaike information 
criteria (AIC) [36] and Bayesian information criteria (BIC) [37] were used to discriminate non-nested 
models. 
Additionally, relative standard errors (RSEs) of parameter estimates, shrinkages, and changes of 
BSV and residual unexplained variability (RUV) estimates were considered. During the model 
developing process, the condition numbers were calculated and no more than 1000 were kept to avoid 
over-parameterisation [38]. 
Model development 
Population PK modelling of MPA and MPAG was conducted using a sequential approach and 
eventually led to a simultaneous modelling of both the parent compound and metabolite. One- or 
two-compartments models with first-order elimination were tested for uMPA and unbound MPAG 
(uMPAG). We further investigated whether MPA absorption was best described by a first- or zero-order 
process, with or without a lagged absorption time (Tlag). The concentrations of uMPAG were not 
determined in our study but were estimated from tMPAG by multiplying the unbound fraction of 
MPAG (FUMPAG), which was fixed at 18% according to a previous study [3].  
The tMPA data was first modelled by adding a linear protein binding compartment as equation 1. 
𝐶𝑡𝑀𝑃𝐴 = 𝐶𝑢𝑀𝑃𝐴 + 𝑘𝐵 × 𝐶𝑢𝑀𝑃𝐴                                            (1)   
where, CtMPA and CuMPA represent total and unbound MPA concentrations, respectively, and kB is the 
protein binding rate constant. In this case, the unbound fraction of MPA (FUMPA) could be expressed as 
equation 2. 
𝐹𝑈𝑀𝑃𝐴 =
𝐶𝑢𝑀𝑃𝐴
𝐶𝑡𝑀𝑃𝐴
=
1
1+𝑘𝐵
                                                         (2)   
The non-linear saturable protein binding model published previously [29, 39] was also evaluated 
using equation 3. 
𝐶𝑏𝑀𝑃𝐴 =
𝐵𝑚𝑎𝑥 × 𝐶𝑢𝑀𝑃𝐴
𝑘𝐷 + 𝐶𝑢𝑀𝑃𝐴
                                                     (3) 
where, CbMPA represents the bound MPA concentration, Bmax is the maximal number of protein binding 
sites, and kD is the dissociation constant representing the uMPA concentration corresponding to 
half-saturation of protein binding. 
To describe the physiological EHC process, the previously published intermittent EHC model [40, 
41] was used with some modifications, in which a gallbladder compartment was introduced to connect 
MPAG and gut compartments. The percentage of MPAG recycled into the systemic circulation (%EHC) 
was described using equation 4. 
%𝐸𝐻𝐶 =
𝑘𝐺𝐺
𝑘𝐺𝐺 + 𝑘𝑒0
× 100                                                (4) 
where, kGG is the transfer rate constant from the MPAG central compartment to the gallbladder and ke0 
is the elimination rate constant of MPAG. 
Several assumptions were made to ensure the model was structurally identifiable [40]: (1) MMF is 
completely and quickly absorbed, (2) the conversion ratio from MMF to MPAG is fixed at 100%, (3) 
MPAG secreted from the gallbladder to intestines is completely deconjugated to MPA and reabsorbed, 
(4) the rate constants associated with each compartment are all first-order and unaffected by the 
recycling, and (5) gallbladder emptying is triggered by meals. Additionally, the gallbladder emptying 
rate constant (kGB) was fixed at 3.708 /h based on previous study [42]. The duration (DGB) of 
gallbladder release was fixed at 0.5 h to ensure that over 90% gallbladder contents would be released 
after each trigger. 
An exponential model was used to describe BSVs for each PK parameter. Exponential, additive, 
and combined models were compared to describe RUVs. Furthermore, the covariance of BSVs was 
estimated with OMEGA BLOCK statement in NONME. Since uMPA, tMPA, and tMPAG 
concentrations were derived from the same sample for each subject, correlations of their RUVs were 
likely to exist. An L2 data item was introduced and the covariance of RUVs was also evaluated with 
SIGMA BLOCK statement [34]. 
After the base model was determined, the following physiologically meaningful covariates were 
investigated: sex, age, body weight (BW), postoperative time (POT), haemoglobin (HB), ALB, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), glomerular 
filtration rate (GFR), CsA daily dose, and co-administration of antacids. GFR was estimated from SCr 
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [43]. 
First, relationships between individual PK parameters and covariates were examined by graphical 
inspection to identify the potential covariates. Then, the identified covariates were tested using a 
stepwise procedure. During the forward inclusion and backward elimination steps, significance levels 
were set at a decrease in OFV > 3.84 (χ2, df = 1, p < 0.05) and an increase in OFV > 10.83 (χ2, df = 1, p 
< 0.001), respectively. The continuous covariates were assessed using a linear and non-linear model, 
and categorical covariates were modelled proportionally. To demonstrate clinical significance, 
covariates were only retained if the effect on the corresponding parameter was > 15% for a categorical 
covariate, or > 15% at the highest or lowest observed covariate value for a continuous covariate [44]. In 
addition, the included covariates were expected to have interpretations of physiological or 
pharmacological mechanisms. 
Model evaluation 
The established model was evaluated by graphical diagnosis. GOF plots included scatterplots of 
population predictions (PRED) and individual predictions (IPRED) versus observed concentrations 
(OBS), as well as conditional weighted residuals (CWRES) versus PRED and time after previous dose 
(TAD). Additionally, 500 bootstraps [45] were applied to assess the reliability and stability of the final 
model. The medians and 2.5%–97.5% intervals from the bootstrap replicates were compared with 
estimates of the final model. 
The final model was further checked by a prediction-corrected visual predictive check (pc-VPC) 
[46] and posterior predictive check (PPC) [47]. Furthermore, 2000 datasets were simulated using the 
final model from the original dataset. For pc-VPC, the observed and simulated concentrations were 
dose-normalised to 750 mg MMF every 12 h. The median simulated concentrations and corresponding 
5%–95% interval were calculated and graphically compared with the observations. PPC was further 
performed to assess if the model appropriately predicted the AUC0-12h of uMPA, tMPA, and tMPAG. 
Simulated and observed AUC0-12h were calculated using the linear trapezoidal rule. Distributions of the 
simulated and observed AUC0-12h were then graphically compared. 
Simulation analyses of effects of significant covariates 
The established final model was used to investigate the effect of the identified covariates on the PK of 
MPA and MPAG. Specifically, 2000 stochastic simulations were performed for virtual subjects 
administered 750 mg MMF every 12 h with different covariate levels. The AUC0-12h values of uMPA, 
tMPA, and tMPAG were estimated using the linear trapezoidal rule and changes in AUC0-12h and FUMPA 
were assessed. 
Results 
Patient characteristics and data descriptions 
A total of 27 full concentration-time profiles containing uMPA, tMPA, and tMPAG data were obtained 
from 20 patients in study 1, including 23 profiles collected within 3 months post-transplantation. 
Sixteen patients had one profile, one had two profiles, and the other three had three profiles. In study 2, 
38 full concentration-time profiles were obtained from 38 patients, including 37 collected beyond 3 
months post-transplantation. The patient characteristics are shown in Table 1. Of these subjects, male 
patients accounted for approximately 78%. The concomitant antacids in study 1 were proton pump 
inhibitors, whereas sodium hydrogen carbonate and compound aluminium hydroxide were 
co-administered in study 2. Significant differences in BW, POT, HB, and ALB as well as doses of 
MMF, CsA, and corticosteroids were observed between the two studies. 
Of the 2229 samples, < 1% (3 uMPA, 1 tMPA, and 10 tMPAG) were below the lower limit of 
quantification and were discarded. In total, 740 uMPA, 741 tMPA, and 734 tMPAG concentration 
measurements were used for the population PK analysis. Multiple uMPA and tMPA peaks attributed to 
EHC were observed at 4–6 and 8–12 h post-dosing in some subjects, whereas no obvious multiple 
peaks were observed for tMPAG. 
Population PK model 
Model development 
A five-compartment model with first-order absorption and elimination adequately described the uMPA, 
tMPA, and uMPAG data. The schematic representation of the final structural model is shown in Figure 
1. The PK profiles of uMPA and uMPAG were characterised using a two- and one-compartment model, 
respectively. Incorporation of Tlag further led to a significant reduction of 387.232 units in the OFV. 
Simultaneously estimation of both Bmax and kD was not feasible; therefore, Bmax was fixed at the 
reported value of 35100 μmol [27]. The non-linear saturable binding from the central compartment did 
not improve the fit (AIC, 1533.614 vs. 1529.537; BIC, 2012.667 vs. 2008.59) more than the linear 
protein binding model did. 
The PK parameters estimated were absorption rate constant (ka), Tlag, apparent clearance of 
uMPA and uMPAG (CLuMPA/F and CLuMPAG/F, respectively), inter-compartmental clearance of uMPA 
(QuMPA/F), apparent central volume of distribution of uMPA and uMPAG (VCuMPA/F and VCuMPAG/F, 
respectively), kB and %EHC. Apparent peripheral volume of distribution of uMPA (VPuMPA/F) could not 
be estimated appropriately and was fixed at the reported literature value of 34300 L [27].  
Considering that the expectation maximisation (EM) algorithm is much more robust and adept at 
handling the large full OMEGA block [34], we initially attempted to assign BSVs to all PK parameters. 
However, our data did not support the estimation of BSV on kB. To maximally enhance the EM 
efficiency, the BSV was assigned to kB and its variance was fixed at 0.01 [34]. Various RUV models 
were tested to describe the residual errors. Incorporation of the additive residual error resulted in 
boundary issues and, therefore, an exponential RUV model was used. 
Based on the visual inspections and clinical plausibility, the effects of BW and sex on CLuMPA/F, 
QuMPA/F, VCuMPA/F, CLuMPAG/F, and VCuMPAG/F; GFR on kB, CLuMPA/F, QuMPA/F, and CLuMPAG/F; ALB on 
kB, VCuMPA/F, and VCuMPAG/F; co-administration of antacids on CLuMPA/F and ka; and tMPAG 
concentrations on kB were further tested using the stepwise method. Of these, the effects of ALB on kB, 
GFR on CLuMPAG/F, BW and sex on QuMPA/F, and co-administration of antacids on ka were included in 
the forward procedure, whereas the effects of co-administration of antacids on ka and sex on QuMPA/F 
showed no significance in the backward step and, thus, were not retained in the final model. The 
forward inclusion and backward elimination steps are summarised in Table S1. 
Although introduction of full variance-covariance matrices for BSVs and RUVs substantially 
decreased the OFV by 288.048 units, the high condition number (1.94 ×10
10
) indicated that the model 
might be ill-conditioned because of over-parameterisation. Finally, the covariances between BSVs for 
VCuMPAG/F and CLuMPAG/F, and between RUVs for uMPA and tMPA were included. This further 
decreased the OFV by 159.478 units with an acceptable condition number (< 150). 
The parameter estimates of final model are provided in Table 2. No significant covariate was 
detected to influence CLuMPA/F, whereas non-linear relationships were found between kB and ALB, and 
between CLuMPAG/F and GFR. RSEs of the parameter estimates were < 25% and 45% for fixed and 
random effects, respectively. Shrinkage values of BSVs and RUVs were < 30% except for %EHC. 
Model evaluation 
The basic GOF plots of the final model are shown in Figure 2 where PRED and IPRED did not show 
obvious bias when plotted against OBS. No evident trend in plots of CWRES versus PRED or TAD 
were found. Over 95% observations were within ±2 CWRES, indicating that the model was 
appropriately unbiased and adequately described the data.  
Out of 500 replicates in the bootstrap analysis, 495 runs converged successfully. The estimated 
parameters based on original dataset were in good agreement with the median bootstrap replicates and 
were within the 2.5%–97.5% intervals obtained from the bootstrap analysis (Table 2), indicating the 
reliability and stability of final model. 
Figure 3 shows the results of the pc-VPC of the final model. Most observed concentrations fell 
within the 90% prediction interval and no obvious discrepancy between observations and simulations 
was found. The PPC suggested that the simulated AUC0-12h values also showed good consistency with 
the observations (Figure 4). The pc-VPC and PPC results showed that the final model was reasonably 
good at predicting the observations. 
Simulations illustrating effect of covariates 
Typical subjects administered 750 mg MMF every 12 h were simulated with different ALB and GFR 
levels. ALB values were set from 20 to 50 g/L with a step of 5 g/L. At each ALB level, the GFR was set 
at 15, 30, 60, 90, and 120 mL/min according to the Kidney Disease: Improving Global Outcomes 
chronic kidney disease classification [48]. Generally, ALB and GFR showed large effects on tMPA and 
tMPAG, respectively, but little effect on uMPA (Figure 5). 
A substantial decrease in tMPA AUC0-12h and increase in FUMPA were observed with decreasing 
ALB concentrations. For subjects with a GFR of 90 mL/min administered 750 mg MMF every 12 h, 
the median tMPA AUC0-12h decreased from 43.03 to 20.66 mg·h/L when ALB concentrations decreased 
from 40 to 20 g/L, whereas the exposure of uMPA and tMPAG remained almost unchanged (<5%). A 
decrease in ALB concentrations from 40 to 20 g/L increased the median FUMPA from 1.86 to 3.80% 
(Figure S1). 
Additionally, a substantial increase in tMPAG AUC0-12h was observed with decreasing GFR. For 
subjects with an ALB concentration of 40 g/L administered 750 mg MMF every 12 h, a reduction in 
GFR from 90 to 15 mL/min led to a 3.65-fold increase in median tMPAG AUC0-12h, while FUMPA and 
the exposure of both uMPA and tMPA were unchanged (Figures 5 and S1).  
The simulations showed that neither ALB nor GFR significantly affected uMPA exposure. For 
patients with lower ALB levels, dose adjustment based on monitoring tMPA would lead to higher risk 
of leucopoenia and infections, resulted by overexposure to uMPA. 
Discussion 
The present study extensively investigated the population PK characteristics of uMPA, tMPA, and 
MPAG in Chinese adult kidney transplant recipients during both the early and stable periods 
post-transplantation. A two-compartment model with first-order absorption and elimination adequately 
described the uMPA data. Furthermore, the uMPA and tMPA were connected using a linear protein 
binding model. 
As shown in Table 3, the population estimate of CLuMPA/F (852 L/h) was comparable to most of 
previously reported values in Caucasians (654–866 L/h) [27-29]. Moreover, the calculated typical value 
of apparent clearance of tMPA (CLtMPA/F, 15.68 L/h) was also comparable to most of previously 
reported values (12.3–20.8 L/h) [17-26]. The population estimate of FUMPA in our study (1.84%) was 
similar to values reported by van Hest et al. [28] and Colom et al. [29] (2.03% and 1.93%, 
respectively). There were no obvious ethnic differences among different populations. 
The stepwise covariate analyses suggested that ALB had significant effects on kB and FUMPA. MPA 
is extensively bound to human ALB, which has more than one binding site on each molecule with 
equivalent binding characteristics [49]. A reduction in ALB decreases the binding sites, which increases 
the FUMPA. 
The simulations showed that changes in ALB concentrations had substantial effects on FUMPA and 
tMPA exposure, but little effect on uMPA exposure, which was consistent with the findings of de 
Winter et al. [27] and van Hest et al. [28]. This could be attributed to the low hepatic extraction ratio of 
MPA. FUMPA tended to increase with decreasing ALB (Figure S1) and the increase in FUMPA caused 
relatively more uMPA to be metabolised and eliminated from the body, thereby decreasing tMPA 
exposure. In contrast, MPA is characterised by a low hepatic extraction ratio of 0.2 [50], and the 
unbound exposure of drugs with low extraction ratio is unaffected by changes in the unbound fraction 
[51]. 
These results suggested that dose adjustment based on tMPA exposure might not be appropriate 
under lower ALB conditions. A reduction in median tMPA AUC0-12h from approximately 43 to 21 
mg·h/L was observed when ALB concentration decreased from 40 to 20 g/L for patients administered 
750 mg MMF every 12 h. However, this observation does not indicate an MMF dose increment is 
necessary because of the unchanged uMPA exposure. Although relationships between uMPA exposure 
and the acute rejection risk have not been fully identified, uMPA has been acknowledged as the 
pharmacologically active component. Moreover, uMPA exposure has been demonstrated to be 
associated with the risk of leucopoenia and infections [52-55]. An increased MMF dose would also 
increase uMPA exposure, placing patients at a higher risk of over-immunosuppression with 
manifestations such as leucopoenia and infections. In such situations, monitoring uMPA exposure 
might be preferable to monitoring tMPA for adjusting the MMF dose. 
Additionally, a gallbladder compartment was introduced to characterise the intermittent EHC 
process in the present study. The EHC process is mediated by multidrug resistance-associated protein 2 
(MRP2), which is inhibited by CsA [56]. All subjects in our study were co-treated with CsA, and 
concentration-time profiles only showed slight multiple peaks attributed to EHC in some individuals. 
Therefore, inhibition of EHC by CsA might likely explain why the final model estimated an extremely 
low %EHC with a high shrinkage (>50%). 
Regarding the metabolite MPAG primarily eliminated through the kidneys, statistically significant 
relationship was found between CLuMPAG/F and kidney function, which was consistent with previous 
studies [20, 25, 27, 28]. Nevertheless, the previously reported competitive protein binding relationship 
between MPA and MPAG [27, 28] was not observed, which might be associated with the relatively 
lower MPAG concentrations (median, 49.79 mg/L). Only 7.6% (56/734) of the tMPAG concentrations 
were > 100 mg/L with a maximum of 177.9 mg/L in our study. At high concentrations, MPAG could 
displace MPA from its protein binding sites. It has been reported in vitro that FUMPA increased 3-fold as 
the MPAG concentration increased from 0 to 800 mg/L [49]. 
There are some limitations in the present study. Firstly, uMPAG data were not available and 
FUMPAG was fixed to previously reported literature values. Thus, the competitive protein binding 
process with a mass balance published by de Winter et al. [27] could not be further investigated. 
Secondly, only one dose level of MMF was administered to most patients in our study, which prevented 
us from investigating the non-linear relationship between MMF dose and MPA exposure as reported by 
de Winter et al. [23]. Lastly, all patients in our study were co-administered with MMF and CsA, 
therefore, our results might only be applicable to patients co-treated with CsA. 
In summary, the established model adequately described the population PK characteristics of 
uMPA, tMPA, and MPAG. Large BSVs and RUVs were still observed, suggesting TDM would be 
necessary for optimisation of MMF therapy. The estimated CLuMPA/F and FUMPA in Chinese kidney 
transplant recipients were comparable to those published previously in Caucasians. In addition, tMPA 
exposure reduced with decreasing ALB, which had little effect on uMPA exposure. Therefore, under 
lower ALB conditions, dose adjustment based on tMPA exposure might place patients at higher risk of 
over-immunosuppression. We recommend monitoring uMPA instead of tMPA to optimise MMF dosing 
for patients with lower ALB concentrations.  
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Table 1 Patient characteristics and clinical covariates 1 
Characteristic Study 1  Study 2 P value 
a
 
median (range) mean±SD  median (range) mean±SD 
Patients, n 20 /  38 / / 
Sex       
Male, n (%) 11 (55) /  34 (89) / < 0.01 
Female, n (%) 9 (45) /  4 (11) / < 0.01 
Age, years 36 (19-61) 37±12  38 (18-62) 38±12 > 0.05 
Body weight, kg 55 (40-71) 54.3±9.8  65 (42-82.5) 65.2±10.2 < 0.001 
Postoperative time, days 10 (3-148) 31±41  298 (70-3084) 620±780 < 0.001 
Mycophenolate mofetil daily dose, mg/day 1500 (750-2000) 1444±313  1000 (1000-2000) 1230±269 < 0.01 
Hemoglobin, g/L 86 (72-134) 93.6±18.6  139 (103-181) 142.6±22.4 < 0.001 
Albumin, g/L 31 (20-43) 32±6.6  44.9 (32.3-50) 44.2±3.9 < 0.001 
Alanine aminotransferase, U/L 24 (10-390) 49.48±78.51  18 (7-64) 21.88±12.65 > 0.05 
Aspartate aminotransferase, U/L 20 (7-139) 33.78±29.32  24 (8.6-86) 28.94±19.88 > 0.05 
Serum creatinine, μmol/L 96 (50-443) 114.41±73.97  104.5 (76-152.9) 108.82±17.27 > 0.05 
Glomerular filtration rate
 b
, mL/min 76.12 (11.17-123.8) 75.58±25.09  74.42 (45.14-102.3) 74.79±14.16 > 0.05 
Concomitant medication       
Ciclosporin daily dose, mg/day 300 (0-400) 282±102  220 (100-400) 231±65 < 0.01 
Corticosteroid daily dose, mg/day 20 (5-675) 49.1±126.1  10 (3-20) 10.8±4.1 < 0.001 
Antacids 
c
, n (%) 6 (22) /  5 (13) / > 0.05 
Aspirin, n (%) 0 (0) /  6 (16) / < 0.05 
Nifedipine, n (%) 4 (15) /  5 (13) / > 0.05 
Diltiazem, n (%) 0 (0) /  7 (18) / < 0.05 
/, not applicable; SD, standard deviation 2 
a
 Differences between groups are determined using the Mann-Whitney U test for continuous variables and Fisher's exact test for categorical data with IBM SPSS Statistics for 3 
Windows (Version 20, IBM Corp., Armonk, NY). 4 
b
 Glomerular filtration rate (GFR) is calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [43]: GFR = 141 × 5 
min(SCr/κ, 1)α × max(SCr/κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black], where SCr is serum creatinine, κ is 62 (μmol/L) for females and 80 (μmol/L) for males, 6 
α is -0.329 for females and -0.411 for males, min indicates the minimum of SCr/κ or 1, and max indicates the maximum of SCr/κ or 1. 7 
c
 Antacids include proton pump inhibitors, sodium hydrogen carbonate and compound aluminium hydroxide.  8 
Table 2 Pharmacokinetic parameter estimates for the final model and Bootstrap results 9 
Parameters Estimates %RSE
a
 Shrinkage(%) 
Bootstrap 
Median 2.5%-97.5% interval 
b
 
OFV 2597.835 / / 2512.239 1876.518-3295.075 
Conditional number 117.84/53.67 / / / / 
Pharmacokinetic parameters      
CLuMPA/F (L/h) 852 7.1 / 852.57 716.95-989.68 
QuMPA/F (L/h)
c
 859 9.0 / 843.98 728.17-1039.38 
Exponent for the effect of BW on QuMPA/F 2.13 15.7 / 2.09 0.95-3.20 
VCuMPA/F (L) 703 17.4 / 723.20 478.32-968.10 
ka (/h) 1.33 9.8 / 1.35 1.13-1.64 
Tlag (h) 0.445 17.6 / 0.439 0.286-0.628 
kB (/h) 
d
 53.4 2.3 / 53.33 46.29-60.76 
Exponent for the effect of ALB on kB 1.07 11.4 / 1.07 0.31-1.65 
VCuMPAG/F (L) 34.4 7.6 / 34.23 29.28-40.02 
CLuMPAG/F (L/h) 
e 
6.59 4.4 / 6.54 5.96-7.30 
Exponent for the effect of GFR on CLuMPAG/F 0.863 11.9 / 0.793 0.329-1.529 
%EHC 5.13 22.8 / 5.08 2.83-7.77 
Between-subject variability       
CLuMPA/F (%CV) 50.6 17.1 3.5 49.9 41.0-59.8 
QuMPA/F (%CV) 44.7 17.9 17.4 42.8 27.3-57.5 
VCuMPA/F (%CV) 82.8 21.3 23.1 79.1 49.6-108.4 
ka (%CV) 43.1 24.9 32.6 44.8 30.5-64.3 
     (Continues) 
Table 2 continued      
Tlag (%CV) 108.2 16.8 7.9 109.7 82.9-164.8 
kB (%CV) 10.0 FIXED / / 10.0 10.0-10.0 
VCuMPAG/F (%CV) 47.9 44.5 14.5 47.8 29.6-65.8 
Covariance between VCuMPAG/F and CLuMPAG/F 0.0869 39.1 / 0.0848 0.0308-0.1491 
CLuMPAG/F (%CV) 31.8 11.7 2.6 32.1 22.9-41.7 
%EHC (%CV) 53.9 32.9 59.7 53.6 15.9-99.0 
Residual unexplained variability      
uMPA (%CV) 47.1 3.6 5.3 47.0 41.5-52.2 
Covariance between uMPA and tMPA 0.109 14.4 / 0.110 0.080-0.141 
tMPA (%CV) 45.8 3.7 5.4 45.6 40.8-49.5 
uMPAG (%CV) 22.0 3.2 4.9 21.4 18.4-24.3 
MPA, mycophenolic acid; MPAG, 7-O-mycophenolic acid glucuronide; tMPA, total MPA; tMPAG, total MPAG; uMPA, unbound MPA; uMPAG, unbound MPAG; /, not 10 
applicable; %CV, percentage coefficient of variation; %EHC, percentage of MPAG recycled into the systemic circulation; %RSE, percentage relative standard error; ALB, 11 
serum albumin; BSV, between-subject variability; BW, body weight; CLuMPA/F, apparent clearance of uMPA; CLuMPAG/F, apparent clearance of uMPAG; GFR, glomerular 12 
filtration rate; ka, absorption rate constant; kB, protein binding rate constant; OFV, objective function value; QuMPA/F, intercompartmental clearance of uMPA; RUV, residual 13 
unexplained variability; Tlag, lagged absorption time; VCuMPA/F, apparent central volume of distribution of uMPA; VCuMPAG/F, apparent central volume of distribution of 14 
uMPAG 15 
a
 %RSE is estimated as the standard error of the estimate divided by the population estimate multiplied by 100. 16 
b
 Based on 495/500 successful bootstrap runs. 17 
c 𝑄𝑢𝑀𝑃𝐴/𝐹 = 859 × [
𝐵𝑊
70
]
2.13
  (𝐿/ℎ) 18 
d 𝑘𝐵 = 53.4 × [
𝐴𝐿𝐵 
40
]
1.07
 (/ℎ) 19 
e 𝐶𝐿𝑢𝑀𝑃𝐴𝐺/F = 6.59 × [
𝐺𝐹𝑅 
80
]
0.863
  (𝐿/ℎ)  20 
The disposition parameter estimates for tMPA and tMPAG are generated by multiplying the unbound concentration based parameters in the original model by the typical 21 
unbound fraction at serum albumin concentration of 40 g/L: 22 
𝐹𝑈𝑀𝑃𝐴 =
1
1 + 𝑘𝐵
=
1
1 + 53.4
= 1.84%  
𝐶𝐿𝑡𝑀𝑃𝐴/𝐹 = 𝐶𝐿𝑢𝑀𝑃𝐴/𝐹 × 𝐹𝑈𝑀𝑃𝐴 = 852 × 1.84% = 15.68 (𝐿/ℎ)  23 
𝑄𝑡𝑀𝑃𝐴/𝐹 = 𝑄𝑢𝑀𝑃𝐴/𝐹 × 𝐹𝑈𝑀𝑃𝐴 = 859 × [
𝐵𝑊
70
]
2.13
× 1.84% = 15.81 × [
𝐵𝑊
70
]
2.13
 (𝐿/ℎ)  24 
𝑉𝐶𝑡𝑀𝑃𝐴/𝐹 = 𝑉𝐶𝑢𝑀𝑃𝐴/𝐹 × 𝐹𝑈𝑀𝑃𝐴 = 703 × 1.84% = 12.94 (𝐿)  25 
𝑉𝑃𝑡𝑀𝑃𝐴/𝐹 = 𝑉𝑃𝑢𝑀𝑃𝐴/𝐹 × 𝐹𝑈𝑀𝑃𝐴 = 34300 × 1.84% = 631.12 (𝐿)  26 
𝐶𝐿𝑡𝑀𝑃𝐴𝐺/𝐹 = 𝐶𝐿𝑢𝑀𝑃𝐴𝐺/𝐹 × 𝐹𝑈𝑀𝑃𝐴𝐺 = 6.59 × [
𝐺𝐹𝑅
80
]
0.863
× 18% = 1.19 × [
𝐺𝐹𝑅
80
]
0.863
 (𝐿/ℎ)  27 
𝑉𝐶𝑡𝑀𝑃𝐴𝐺/𝐹 = 𝑉𝐶𝑢𝑀𝑃𝐴𝐺/𝐹 × 𝐹𝑈𝑀𝑃𝐴𝐺 = 34.4 × 18% = 6.12 (𝐿)  28 
where, CLtMPA/F is apparent clearance of tMPA, CLtMPAG/F is apparent clearance of tMPAG, FUMPA is unbound fraction of MPA, FUMPAG is unbound fraction of MPAG, 29 
QtMPA/F is intercompartmental clearance of tMPA, VCtMPA/F is apparent central volume of distribution of tMPA, VCtMPAG/F is apparent central volume of distribution of 30 
tMPAG and VPtMPA/F is apparent peripheral volume of distribution of tMPA  31 
Table 3 Previously published population pharmacokinetic analysis of unbound and total mycophenolic acid  32 
References Present study 
Okour et al,  
2018[30]   
Colom et al,  
2018[29] 
van Hest et al,  
2009[28] 
de Winter et al,  
2009[27] 
Number of patients 58 92 56 88 75 
Concomitant CNI  CsA CsA /TAC CsA /TAC CsA CsA /TAC 
Postoperative time 3-3084 days / 7 days~1 year 7~148 days 4~155 days 
Structure model MPA: 2 CMT 
MPAG: 1 CMT 
MPA: 1 CMT  
MPAG: 1 CMT  
acyl-MPAG :1 CMT  
MPA: 2 CMT 
MPA: 2 CMT 
MPAG: 2 CMT 
MPA: 2 CMT  
MPAG: 1 CMT 
pharmacokinetic parameter 
a
      
FUMPA (%) 1.84 
b
 2.4 1.93 
b
 2.03 
b
 / 
CLuMPA/F (L/h) 852 1832 654 866 747 
VCuMPA/F (L) 703 5630 18.3 2990 189 
QuMPA/F (L/h) 859 / 749 1210 2010 
VPuMPA/F (L) 34300 FIXED / 29100 6240 34300 
Between-subject variability      
CLuMPA/F (%CV) 50.6 30.1  26.81 25 97 
VCuMPA/F (%CV) 82.8 35.5  99.45 91 116 
Between-occasion variability      
CLuMPA/F (CV%) / / 40.9 / / 
VCuMPA/F (CV%) / / 137.6 / / 
Residual unexplained variability      
uMPA Exponential: 47.1% proportional: 40.5% proportional: 58.3% log-add: 0.44 log-add: 0.993 
tMPA Exponential: 45.8% proportional: 35.8% proportional: 46.9% log-add: 0.42 log-add: 0.52 
MPA, mycophenolic acid; MPAG, 7-O-mycophenolic acid glucuronide; tMPA, total MPA; uMPA, unbound MPA; /, not applicable or not available; %CV, percentage 33 
coefficient of variation; acyl-MPAG, acyl-glucuronide mycophenolic acid; CLuMPA/F, apparent clearance of uMPA; CMT, compartment; CNI, calcineurin inhibitor; CsA, 34 
ciclosporin; FUMPA, unbound fraction of MPA; log-add, log-transformed additive; QuMPA/F, intercompartmental clearance of uMPA; TAC, tacrolimus; VCuMPA/F, apparent 35 
central volume of distribution of uMPA; VPuMPA/F, apparent peripheral volume of distribution of uMPA 36 
a 
Represented as typical reference subjects: 1) body weight 70 kg, 2) serum albumin concentration 40 g/L, 3) glomerular filtration rate 90 mL/min, 4) co-treated with CsA 300 37 
mg per day, 5) total MPAG concentration 0.1 mmol/L.  38 
b
 calculated based on the protein binding rate constant.39 
Figure legends 
Figure 1 Schematic representation of the final structural model characterising the linear protein 
binding and intermittent EHC processes. In this model, mealtimes are used as an index of 
gallbladder emptying. This process is assumed to occurrence at the specific time points (mealtimes) 
with a first-order rate constant and a certain duration. MMF, mycophenolate mofetil; MPA, 
mycophenolic acid; MPAG, 7-O-mycophenolic acid glucuronide; tMPA, total MPA; tMPAG, total 
MPAG; uMPA, unbound MPA; uMPAG, unbound MPAG; ALB, serum albumin; BW, body weight; 
DGB, duration of gallbladder emptying; EHC, enterohepatic circulation; %EHC, percentage of MPAG 
recycled into the systemic circulation; FUMPA, unbound fraction of MPA; FUMPAG, unbound fraction of 
MPAG; GFR, glomerular filtration rate; k23, transfer rate constant from uMPA central compartment to 
peripheral compartment; k24, elimination rate constant of uMPA; k32, transfer rate constant from uMPA 
peripheral compartment to central compartment; ka, absorption rate constant; kB, protein binding rate 
constant; ke0, elimination rate constant of uMPAG; kGB, gallbladder emptying rate constant; kGG, 
transfer rate constant from uMPAG central compartment to gallbladder; Tlag, lagged absorption time; 
VCuMPA/F, apparent central volume of distribution of uMPA; VCuMPAG/F, apparent central volume of 
distribution of uMPAG; VPuMPA/F, apparent peripheral volume of distribution of uMPA 
Figure 2 Goodness-of-fit plots of final model for uMPA, tMPA and tMPAG. (A) population 
predictions versus observations; (B) individual predictions versus observations; (C) population 
predictions versus conditional weighted residuals; (D) time after previous dose versus conditional 
weighted residuals. Red dashed lines and gray-shaded areas represent the locally weighted regression 
line and 95% confidence interval, respectively. In plots A and B, black solid lines represent the line of 
unity. In plots C and D, black solid and dashed lines represent the y=0 and y=±1.96 reference lines, 
respectively. tMPA, total mycophenolic acid (MPA); tMPAG, total 7-O-mycophenolic acid glucuronide; 
uMPA, unbound MPA 
Figure 3 Prediction-corrected visual predictive check plots of final model for uMPA, tMPA and 
tMPAG. Blue dots represent the observed concentrations. Red solid lines represent the median of 
observations, and the semitransparent red fields represent the simulation-based 95% CIs for the median. 
The observed 5th and 95th percentiles are presented with red dashed lines, and the simulation-based 95% 
CIs for corresponding percentiles are shown as semitransparent blue fields. In general, the median and 
5th and 95th percentile lines of observations fall inside the area of the corresponding 95% CIs. 
Additionally, the majority of observed concentrations fall within the 90% prediction interval, which 
demonstrates that the predicted variability does not exceed the observed variability. CIs, confidence 
intervals; tMPA, total mycophenolic acid (MPA); tMPAG, total 7-O-mycophenolic acid glucuronide; 
uMPA, unbound MPA 
Figure 4 Posterior predictive check graphics of final model for uMPA, tMPA and tMPAG. The 
histograms represent the distribution of simulations. Black and blue solid lines represent the medians of 
observations and simulations, respectively. The observed 5th and 95th percentiles are presented by 
black dashed lines, and the simulated 5th and 95th percentiles are presented by blue dashed lines. The 
simulated AUC0-12h values present good consistency with observations. In particular, the 5th percentiles 
of simulations and observations for uMPA and tMPAG, as well as the medians of simulations and 
observations for tMPAG, are completely overlapped in the graphics. AUC0-12h, area under the 
concentration-time curve within 12-h dose-interval; tMPA, total mycophenolic acid (MPA); tMPAG, 
total 7-O-mycophenolic acid glucuronide; uMPA, unbound MPA 
Figure 5 Model-predicted covariate effects on AUC0-12h of uMPA, tMPA and tMPAG. Black 
squares represent median values and error bars represent 95% confidence intervals of the normalized 
exposure ratios relative to the typical reference subject (ALB 40 g/L, GFR 90 mL/min) across 2000 
simulation replicates. The vertical red dashed lines show an exposure ratio of 1 relative to the reference 
subject. ALB, serum albumin; AUC0-12h, area under the concentration-time curve within 12-h 
dose-interval; GFR, glomerular filtration rate; tMPA, total mycophenolic acid (MPA); tMPAG, total 
7-O-mycophenolic acid glucuronide; uMPA, unbound MPA  
Oral MMF 
%𝐄𝐇𝐂 =
𝒌𝑮𝑮
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Supporting information 
Table S1  
Key covariate model development steps 
Figure S1  
Model-predicted covariate effect on unbound fraction of MPA. Black squares represent median values and error bars represent 95% 
confidence intervals of unbound fraction of MPA across 2000 simulation replicates. GFR, glomerular filtration rate; MPA, 
mycophenolic acid
Table S1 Key covariate model development steps 
Model No. Model description OFV ΔOFV Significance a df Screening results Comparator 
001 Base model 2896.614 / / / / / 
Forward inclusion step 1       
101 Add BW on CLuMPA/F  2895.068 -1.546 No 1 / 001 
102 Add BW on QuMPA/F 2870.053 -26.561 Yes 1 / 001 
103 Add BW on VCuMPA/F 2897.441 0.827 No 1 / 001 
104 Add BW on CLuMPAG/F  2895.062 -1.552 No 1 / 001 
105 Add BW on VCuMPAG/F 2898.246 1.632 No 1 / 001 
106 Add GFR on kB 2888.127 -8.487 Yes 1 / 001 
107 Add GFR on CLuMPA/F 2900.043 3.429 No 1 / 001 
108 Add GFR on QuMPA/F 2898.741 2.127 No 1 / 001 
109 Add GFR on CLuMPAG/F 2859.631 -36.983 Yes 1 / 001 
110 Add ALB on kB 2826.643 -69.971 Yes 1 Included  001 
111 Add ALB on VCuMPA/F 2885.293 -11.321 Yes 1 / 001 
112 Add ALB on VCuMPAG/F 2931.664 35.05 No 1 / 001 
113 Add ANTAC on CLuMPA/F 2896.066 -0.548 No 1 / 001 
114 Add ANTAC on ka 2891.800 -4.814 Yes 1 / 001 
115 Add GEND on CLuMPA/F 2901.078 4.464 No 1 / 001 
116 Add GEND on QuMPA/F 2875.397 -21.217 Yes 1 / 001 
117 Add GEND on VCuMPA/F 2896.181 -0.433 No 1 / 001 
118 Add GEND on CLuMPAG/F 2898.042 1.428 No 1 / 001 
119 Add GEND on VCuMPAG/F 2897.878 1.264 No 1 / 001 
120 Add MPAG concentration on kB 2898.906 2.292 No 1 / 001 
121 Add MPAG trough concentration on kB 2899.638 3.024 No 1 / 001 
Forward inclusion step 2       
201 Add BW on QuMPA/F 2794.131 -32.512 Yes 1 / 110 
202 Add GFR on kB 2832.015 5.372 No 1 / 110 
203 Add GFR on CLuMPAG/F 2786.521 -40.122 Yes 1 Included  110 
204 Add ALB on VCuMPA/F 2812.156 -14.487 Yes 1 / 110 
205 Add ANTAC on ka 2819.256 -7.387 Yes 1 / 110 
206 Add GEND on QuMPA/F 2805.960 -20.683 Yes 1 / 110 
Forward inclusion step 3       
301 Add BW on QuMPA/F 2757.313 -29.208 Yes 1 Included 203 
302 Add ALB on VCuMPA/F 2766.204 -20.317 Yes 1 / 203 
303 Add ANTAC on ka 2776.640 -9.881 Yes 1 / 203 
304 Add GEND on QuMPA/F 2767.085 -19.436 Yes 1 / 203 
Forward inclusion step 4       
401 Add ALB on VCuMPA/F 2743.568 -13.745 Yes 1 Not included b 301 
402 Add ANTAC on ka 2750.300 -7.013 Yes 1 / 301 
403 Add GEND on QuMPA/F 2749.149 -8.164 Yes 1 Included 301 
Forward inclusion step 5       
501 Add ALB on VCuMPA/F 2732.134 -17.015 Yes 1 Not included b 401 
502 Add ANTAC on ka 2739.109 -10.04 Yes 1 Included 401 
Forward inclusion step 6       
601 Add ALB on VCuMPA/F 2725.397 -13.712 Yes 1 Not included b 502 
Backward elimination step 1       
1001 Eliminate ALB from kB 2817.487 78.378 Yes 1 Retained  502 
1002 Eliminate GFR from CLuMPAG/F 2778.187 39.078 Yes 1 Retained  502 
1003 Eliminate BW from QuMPA/F 2758.365 19.256 Yes 1 Retained  502 
1004 Eliminate GEND from QuMPA/F 2750.300 11.191 Yes 1 Retained  502 
1005 Eliminate ANTAC from ka 2749.149 10.04 No 1 Eliminated  502 
Backward elimination step 2       
1011 Eliminate ALB from kB 2831.266 82.117 Yes 1 Retained  1005 
1012 Eliminate GFR from CLuMPAG/F 2786.818 37.699 Yes 1 Retained  1005 
1013 Eliminate BW from QuMPA/F 2767.085 17.936 Yes 1 Retained  1005 
1014 Eliminate GEND from QuMPA/F 2757.313 8.164 No 1 Eliminated  1005 
Backward elimination step 3       
1021 Eliminate ALB from kB 2831.921 74.608 Yes 1 Retained  1014 
1022 Eliminate GFR from CLuMPAG/F 2794.131 36.818 Yes 1 Retained  1014 
1023 Eliminate BW from QuMPA/F 2786.521 29.208 Yes 1 Retained  1014 
ALB, serum albumin concentration; ANTAC, antacid; BW, body weight; CLuMPA/F, apparent clearance of uMPA; CLuMPAG/F, apparent clearance of uMPAG; df, degree of freedom; GEND, 
gender; GFR, glomerular filtration rate; ka, absorption rate constant; kB, protein binding rate constant; MPAG, 7-O-mycophenolic acid glucuronide; OFV, objective function value; QuMPA/F, 
intercompartmental clearance of uMPA; uMPA, unbound mycophenolic acid; uMPAG, unbound MPAG; VCuMPA/F, apparent central volume of distribution of uMPA; VCuMPAG/F, apparent 
central volume of distribution of uMPAG; ΔOFV, change in OFV 
a Significance levels are set at a decrease in OFV of >3.84 (χ2, df =1, p <0.05) during the forward inclusion step and an increase in OFV of >10.83 (χ2, df =1, p <0.001) during the backward 
elimination step, respectively. 
b Addition of ALB on VCuMPA results in a significant decrease in OFV. However, it also leads to an increase in the between-subject variability (BSV) on VCuMPA of over 60%. Thus, ALB is not 
included as a significant covariate.  
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Figure S1 Model-predicted covariate effect on unbound fraction of MPA. Black squares represent median values and error bars represent 95% confidence 
intervals of unbound fraction of MPA across 2000 simulation replicates. GFR, glomerular filtration rate; MPA, mycophenolic acid
